Study identifier:BY217/CP-059
ClinicalTrials.gov identifier:NCT00940329
EudraCT identifier:N/A
CTIS identifier:N/A
Investigation on the cardiovascular and pharmacokinetic interaction between oral roflumilast and inhaled formoterol in healthy subjects
Healthy
Phase 1
Yes
Roflumilast
Male
27
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: Treatment A | Drug: Roflumilast Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18) |
Active Comparator: Treatment B | Drug: Roflumilast Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18) |